Circulating soluble receptor for advanced glycation end products is inversely associated with body mass index and waist/hip ratio in the general population

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 2, 2009, Pages 129-134

  Norata, Giuseppe Danilo ^a,b   Garlaschelli, Katia ^b   Grigore, Liliana ^b   Tibolla, Gianpaolo ^a   Raselli, Sara ^b   Redaelli, Laura ^b   Buccianti, Gherardo ^c   Catapano, Alberico Luigi ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b Ospedale Bassini   (Italy)

^c SAN GERARDO HOSPITAL   (Italy)

Author keywords

Apolipoproteins; BMI; sRAGE

Indexed keywords

ADVANCED GLYCOSYLATION END PRODUCT RECEPTOR; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; APOLIPOPROTEIN A1; IMMUNOGLOBULIN RECEPTOR;

AGED; ARTICLE; BLOOD; BODY MASS; CARDIOVASCULAR DISEASE; FEMALE; GENETICS; GLUCOSE BLOOD LEVEL; HUMAN; MALE; MIDDLE AGED; OBESITY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; WAIST HIP RATIO;

AGED; APOLIPOPROTEIN A-I; BLOOD GLUCOSE; BODY MASS INDEX; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE; MIDDLE AGED; OVERWEIGHT; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, IMMUNOLOGIC; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; WAIST-HIP RATIO;

EID: 60349094487     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.03.004     Document Type: Article

References (18)

1. Goldin A., Beckman J.A., Schmidt A.M., and Creager M.A. Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation 114 (2006) 597-605
2. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., et al. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem J 370 (2003) 1097-1109
3. Bucciarelli L.G., Wendt T., Qu W., Lu Y., Lalla E., Rong L.L., et al. RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice. Circulation 106 (2002) 2827-2835
4. Park L., Raman K.G., Lee K.J., Lu Y., Ferran Jr. L.J., Chow W.S., et al. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4 (1998) 1025-1031
5. Wautier J.L., Zoukourian C., Chappey O., Wautier M.P., Guillausseau P.J., Cao R., et al. Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy. Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. J Clin Invest 97 (1996) 238-243
6. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., et al. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J Clin Endocrinol Metab 91 (2006) 4628-4634
7. Katakami N., Matsuhisa M., Kaneto H., Matsuoka T.A., Sakamoto K., Nakatani Y., et al. Decreased endogenous secretory advanced glycation end product receptor in type 1 diabetic patients: its possible association with diabetic vascular complications. Diabetes Care 28 (2005) 2716-2721
8. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., et al. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler Thromb Vasc Biol 25 (2005) 1032-1037
9. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens 23 (2005) 1725-1729
10. Koyama H., Shoji T., Yokoyama H., Motoyama K., Mori K., Fukumoto S., et al. Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 25 (2005) 2587-2593
11. Hudson B.I., Stickland M.H., Futers T.S., and Grant P.J. Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50 (2001) 1505-1511
12. Norata G.D., Ongari M., Garlaschelli K., Raselli S., Grigore L., and Catapano A.L. Plasma resistin levels correlate with determinants of the metabolic syndrome. Eur J Endocrinol 156 (2007) 279-284
13. Norata G.D., Garlaschelli K., Ongari M., Raselli S., Grigore L., and Catapano A.L. Effects of fractalkine receptor variants on common carotid artery intima-media thickness. Stroke 37 (2006) 1558-1561
14. Norata G.D., Ongari M., Garlaschelli K., Tibolla G., Grigore L., Raselli S., et al. Effect of the -420C/G variant of the resistin gene promoter on metabolic syndrome, obesity, myocardial infarction and kidney dysfunction. J Intern Med 262 (2007) 104-112
15. Norata G.D., Garlaschelli K., Ongari M., Raselli S., Grigore L., Benvenuto F., et al. Effect of the toll-like receptor 4 (TLR-4) variants on intima-media thickness and monocyte-derived macrophage response to LPS. J Intern Med 258 (2005) 21-27
16. Mukherjee T.K., Reynolds P.R., and Hoidal J.R. Differential effect of estrogen receptor alpha and beta agonists on the receptor for advanced glycation end product expression in human microvascular endothelial cells. Biochim Biophys Acta 1745 (2005) 300-309
17. Mukhopadhyay S., and Mukherjee T.K. Bridging advanced glycation end product, receptor for advanced glycation end product and nitric oxide with hormonal replacement/estrogen therapy in healthy versus diabetic postmenopausal women: a perspective. Biochim Biophys Acta 1745 (2005) 145-155
18. Pettersson-Fernholm K., Forsblom C., Hudson B.I., Perola M., Grant P.J., and Groop P.H. The functional -374 T/A RAGE gene polymorphism is associated with proteinuria and cardiovascular disease in type 1 diabetic patients. Diabetes 52 (2003) 891-894